Holen Sie sich die Stockscreener-App
67.09
5.21%
3.32
Handel nachbörslich:
67.09
Schlusskurs vom Vortag:
$63.77
Offen:
$63.89
24-Stunden-Volumen:
956.96K
Relative Volume:
0.89
Marktkapitalisierung:
$5.07B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-16.98
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+2.36%
1M Leistung:
+23.10%
6M Leistung:
+66.48%
1J Leistung:
+31.29%
1-Tages-Spanne:
$63.21
$67.59
1-Wochen-Bereich:
$62.15
$67.59
52-Wochen-Spanne:
$33.19
$67.59
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
67.09 | 4.82B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Merus NV stock hits all-time high at 67.59 USD By Investing.com - Investing.com South Africa
Merus NV stock hits all-time high at 67.59 USD - Investing.com
How Rising Losses and Strong Cash Reserves at Merus (MRUS) Have Changed Its Investment Story - simplywall.st
Is Merus' (MRUS) Rising Revenue and Widening Losses Changing Its Investment Story? - simplywall.st
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Merus Showcases Revolutionary Cancer Treatment Platform at Major Growth Conference: CEO Presentation Details - Stock Titan
Merus to sustain operations through 2028 with $892 million in cash and equivalents. - AInvest
Merus sees cash runway at least into 2028 - TipRanks
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Merus reports Q2 EPS ($2.23), consensus ($1.15) - TipRanks
Merus (MRUS) Q2 Revenue Falls Short of Expectations, Exciting Cl - GuruFocus
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update - GlobeNewswire
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Merus N.V. Forms Bullish Flag — Upside AheadTop Performing Stock Insights Released Daily - metal.it
Merus Awards Massive $15.7M Stock Options Package to Key New Hires in Oncology Push - Stock Titan
What is Merus N.V. company’s growth strategyInvest confidently with professional guidance - Jammu Links News
Does Merus N.V. stock perform well during market downturnsStrong return on assets - Jammu Links News
What is the risk reward ratio of investing in Merus N.V. stockUnlock superior stock analysis tools - Jammu Links News
How volatile is Merus N.V. stock compared to the marketBuild wealth faster with expert stock picks - Jammu Links News
What institutional investors are buying Merus N.V. stockGet daily updates on promising stocks - Jammu Links News
Should I hold or sell Merus N.V. stock in 2025Get insider insights into market trends - Jammu Links News
What makes Merus N.V. stock price move sharplyConsistent high-yield stocks - Jammu Links News
Is it the right time to buy Merus N.V. stockHigh-yield trading alerts - Jammu Links News
10 Best All-Time High Stocks to Buy According to Analysts - Insider Monkey
Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for HNSCC Treatment - TipRanks
Merus N.V. Flashes Buy Signal on Multi Timeframe ChartWeekly Setup With 3x Return Potential Published - metal.it
Options Data Show Bullish Bias in Merus N.V.Multi-Bagger Potential Stock Forecast Tools Released - metal.it
RSI Crosses Above 30 for Merus N.V. — Reversal in SightShort Term Setup With Predictive Chart Confirmed - metal.it
When is Merus N.V. stock expected to show significant growthStock Market Opportunities For Every Investor - Jammu Links News
Why is Merus N.V. stock attracting strong analyst attentionGrow your portfolio with growth-oriented stocks - Jammu Links News
What are Merus N.V. company’s key revenue driversRapid wealth creation - jammulinksnews.com
Merus NV stock reaches all-time high at 66.44 USD By Investing.com - Investing.com South Africa
Merus NV stock reaches all-time high at 66.44 USD - Investing.com
Why Merus N.V. stock is on top investor watchlistsHigh-impact stock picks - jammulinksnews.com
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):